Low molecular weight dextran sulfate binds to human myoblasts and improves their survival after transplantation in mice

Cell Transplantation

Volumn 22, Issue 7, 2013, Pages 1213-1226

  Laumonier, Thomas ^a   Pradier, Amandine ^a   Hoffmeyer, Pierre ^a   Kindler, Vincent ^a   Menetrey, Jacques ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bioluminescence; Cell survival; Dextran sulfate (DXS); Mice; Myoblast transplantation

Indexed keywords

DEXTRAN SULFATE; INTERCELLULAR ADHESION MOLECULE 1; RENILLA LUCIFERIN 2 MONOOXYGENASE; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CELL DEATH; CELL DIFFERENTIATION; CELL ENGINEERING; CELL MATURATION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MOLECULAR WEIGHT; MOUSE; MYOBLAST; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD, PRESCHOOL; DEXTRAN SULFATE; FEMALE; GRAFT SURVIVAL; HUMANS; INFANT; KILLER CELLS, NATURAL; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED NOD; MOLECULAR WEIGHT; MYOBLASTS; NECROSIS; STAUROSPORINE; TRANSPLANTATION, HETEROLOGOUS;

MUS; RENILLA LUCIFERASE;

EID: 84879576439     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X657224     Document Type: Article

References (39)

1. Arnaudeau, S.; Holzer, N.; Konig, S.; Bader, C. R.; Bernheim, L. Calcium sources used by postnatal human myoblasts during initial differentiation. J. Cell. Physiol. 208(2):435-445; 2006.
2. Banz, Y.; Gajanayake, T.; Matozan, K.; Yang, Z.; Rieben, R. Dextran sulfate modulates MAP kinase signaling and reduces endothelial injury in a rat aortic clamping model. J. Vasc. Surg. 50(1):161-170; 2009.
3. Banz, Y.; Rieben, R. Endothelial cell protection in xenotransplantation: Looking after a key player in rejection. Xenotransplantation 13(1):19-30; 2006.
4. Baroffio, A.; Aubry, J. P.; Kaelin, A.; Krause, R. M.; Hamann, M.; Bader, C. R. Purification of human muscle satellite cells by flow cytometry. Muscle Nerve 16(5):498-505; 1993.
5. Bouchentouf, M.; Benabdallah, B. F.; Rousseau, J.; Schwartz, L. M.; Tremblay, J. P. Induction of anoikis following myoblast transplantation into SCID mouse muscles requires the Bit1 and FADD pathways. Am. J. Transplant. 7(6):1491-1505; 2007.
6. Bouchentouf, M.; Benabdallah, B. F.; Tremblay, J. P. Myoblast survival enhancement and transplantation success improvement by heat-shock treatment in mdx mice. Transplantation 77(9):1349-1356; 2004.
7. Figarella-Branger, D.; Civatte, M.; Bartoli, C.; Pellissier, J. F. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28(6):659-682; 2003.
8. Flexner, C.; Barditch-Crovo, P. A.; Kornhauser, D. M.; Farzadegan, H.; Nerhood, L. J.; Chaisson, R. E.; Bell, K. M.; Lorentsen, K. J.; Hendrix, C. W.; Petty, B. G.; Lietman, P. S. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother. 35(12): 2544-2550; 1991.
9. Gerard, C.; Forest, M. A.; Beauregard, G.; Skuk, D.; Tremblay, J. P. Fibrin gel improves the survival of transplanted myoblasts. Cell Transplant. 21(1):127-137; 2012.
10. Goebels, N.; Michaelis, D.; Wekerle, H.; Hohlfeld, R. Human myoblasts as antigen-presenting cells. J. Immunol. 149(2):661-667; 1992.
11. Goudenege, S.; Lamarre, Y.; Dumont, N.; Rousseau, J.; Frenette, J.; Skuk, D.; Tremblay, J. P. Laminin-111: A potential therapeutic agent for Duchenne muscular dystrophy. Mol. Ther. 18(12):2155-2163; 2010.
12. Guerette, B.; Asselin, I.; Skuk, D.; Entman, M.; Tremblay, J. P. Control of inflammatory damage by anti-LFA-1: Increase success of myoblast transplantation. Cell Transplant. 6(2): 101-107; 1997.
13. Guerette, B.; Skuk, D.; Celestin, F.; Huard, C.; Tardif, F.; Asselin, I.; Roy, B.; Goulet, M.; Roy, R.; Entman, M.; Tremblay, J. P. Prevention by anti-LFA-1 of acute myoblast death following transplantation. J. Immunol. 159(5):2522-2531; 1997.
14. Guerette, B.; Tremblay, G.; Vilquin, J. T.; Asselin, I.; Gingras, M.; Roy, R.; Tremblay, J. P. Increased interferon-g mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. Muscle Nerve 19(7): 829-835; 1996.
15. Hodgetts, S. I.; Spencer, M. J.; Grounds, M. D. A role for natural killer cells in the rapid death of cultured donor myoblasts after transplantation. Transplantation 75(6): 863-871; 2003.
16. Holzer, N.; Hogendoorn, S.; Zurcher, L.; Garavaglia, G.; Yang, S.; Konig, S.; Laumonier, T.; Menetrey, J. Autologous transplantation of porcine myogenic precursor cells in skeletal muscle. Neuromuscul. Disord. 15(3):237-244; 2005.
17. Johann, S.; Blumel, G.; Lipp, M.; Forster, R. A versatile flow cytometry-based assay for the determination of shortand long-term natural killer cell activity. J. Immunol. Methods 185(2):209-216; 1995.
18. Kung, G.; Konstantinidis, K.; Kitsis, R. N. Programmed necrosis, not apoptosis, in the heart. Circ. Res. 108(8): 1017-1036; 2011.
19. Laumonier, T.; Mohacsi, P. J.; Matozan, K. M.; Banz, Y.; Haeberli, A.; Korchagina, E. Y.; Bovin, N. V.; Vanhove, B.; Rieben, R. Endothelial cell protection by dextran sulfate: A novel strategy to prevent acute vascular rejection in xenotransplantation. Am. J. Transplant. 4(2):181-187; 2004.
20. Laumonier, T.; Walpen, A. J.; Maurus, C. F.; Mohacsi, P. J.; Matozan, K. M.; Korchagina, E. Y.; Bovin, N. V.; Vanhove, B.; Seebach, J. D.; Rieben, R. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. Transplantation 76(5):838-843; 2003.
21. Laumonier, T.; Yang, S.; Konig, S.; Chauveau, C.; Anegon, I.; Hoffmeyer, P.; Menetrey, J. Lentivirus mediated HO-1 gene transfer enhances myogenic precursor cell survival after autologous transplantation in pig. Mol. Ther. 16(2): 404-410; 2008.
22. Lian, R. H.; Kotwal, G. J.; Hunt, L. A.; Wilson, M. A.; Justus, D. E. Dextran sulfate inhibits IFN-g-induced Jak- Stat pathway in human vascular endothelial cells. Cell. Immunol. 192(2):140-148; 1999.
23. Lian, R. H.; Kotwal, G. J.; Wellhausen, S. R.; Hunt, L. A.; Justus, D. E. IFN-g-induced MHC class II gene expression is suppressed in endothelial cells by dextran sulfate. J. Immunol. 157(2):864-873; 1996.
24. Mendell, J. R.; Kissel, J. T.; Amato, A. A.; King, W.; Signore, L.; Prior, T. W.; Sahenk, Z.; Benson, S.; McAndrew, P. E.; Rice, R.; Nagaraja, H.; Stephens, R.; Lantry, L.; Morris, G. E.; Burghes, A. H. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N. Engl. J. Med. 333(13): 832-838; 1995.
25. Millard, A. L.; Spirig, R.; Mueller, N. J.; Seebach, J. D.; Rieben, R. Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. Mol. Immunol. 47(14):2349-2358; 2010.
26. Partridge, T. A.; Morgan, J. E.; Coulton, G. R.; Hoffman, E. P.; Kunkel, L. M. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337(6203):176-179; 1989.
27. Pradier, A.; Passweg, J.; Villard, J.; Kindler, V. Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity. Cell Transplant. 20(5):681-691; 2011.
28. Riederer, I.; Negroni, E.; Bigot, A.; Bencze, M.; Di Santo, J.; Aamiri, A.; Butler-Browne, G.; Mouly, V. Heat shock treatment increases engraftment of transplanted human myoblasts into immunodeficient mice. Transplant. Proc. 40(2):624-630; 2008.
29. Schmidt, P.; Magnusson, C.; Lundgren, T.; Korsgren, O.; Nilsson, B. Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor. Transplantation 86(11):1523-1530; 2008.
30. Skuk, D.; Caron, N.; Goulet, M.; Roy, B.; Espinosa, F.; Tremblay, J. P. Dynamics of the early immune cellular reactions after myogenic cell transplantation. Cell Transplant. 11(7):671-681; 2002.
31. Skuk, D.; Caron, N. J.; Goulet, M.; Roy, B.; Tremblay, J. P. Resetting the problem of cell death following musclederived cell transplantation: Detection, dynamics and mechanisms. J. Neuropathol. Exp. Neurol. 62(9):951-967; 2003.
32. Skuk, D.; Goulet, M.; Roy, B.; Piette, V.; Cote, C. H.; Chapdelaine, P.; Hogrel, J. Y.; Paradis, M.; Bouchard, J. P.; Sylvain, M.; Lachance, J. G.; Tremblay, J. P. First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: Eighteen months follow-up. Neuromuscul. Disord. 17(1):38-46; 2007.
33. Skuk, D.; Paradis, M.; Goulet, M.; Tremblay, J. P. Ischemic central necrosis in pockets of transplanted myoblasts in nonhuman primates: Implications for cell-transplantation strategies. Transplantation 84(10):1307-1315; 2007.
34. Smythe, G. M.; Hodgetts, S. I.; Grounds, M. D. Immunobiology and the future of myoblast transfer therapy. Mol. Ther. 1(4):304-313; 2000.
35. Spirig, R.; Gajanayake, T.; Korsgren, O.; Nilsson, B.; Rieben, R. Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. Mol. Immunol. 45(16):4084-4094; 2008.
36. Thorrez, L.; Shansky, J.; Wang, L.; Fast, L.; VandenDriessche, T.; Chuah, M.; Mooney, D.; Vandenburgh, H. Growth, differentiation, transplantation and survival of human skeletal myofibers on biodegradable scaffolds. Biomaterials 29(1): 75-84; 2008.
37. Tremblay, J. P.; Skuk, D. Another new "super muscle stem cell" leaves unaddressed the real problems of cell therapy for duchenne muscular dystrophy. Mol. Ther. 16(12):1907-1909; 2008.
38. Wiendl, H.; Hohlfeld, R.; Kieseier, B. C. Immunobiology of muscle: Advances in understanding an immunological microenvironment. Trends Immunol. 26(7):373-380; 2005.
39. Wuillemin, W. A.; te Velthuis, H.; Lubbers, Y. T.; de Ruig, C. P.; Eldering, E.; Hack, C. E. Potentiation of C1 inhibitor by glycosaminoglycans: Dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J. Immunol. 159(4):1953-1960; 1997.